诚达药业(301201.SZ)：预计2025年亏损1100万元至1800万元

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) expects a loss of 11 million to 18 million yuan in 2025, with a non-recurring loss of 27.5 million to 34.5 million yuan [1] Group 1: Financial Performance - The company has implemented effective sales strategies and steadily advanced market development, resulting in revenue growth during the reporting period [1] - Fixed asset scale has expanded due to the completion and delivery of fundraising projects, leading to increased depreciation and amortization expenses [1] Group 2: Investment and Development - The wholly-owned subsidiary, Shanghai Jiuqian Cheng Bio-pharmaceutical Co., Ltd., is still in the innovative drug research and development phase and has not yet generated revenue [1] - The company has conducted impairment tests on inventory and investment properties at the end of the reporting period, recognizing corresponding impairment provisions based on prudence [1]